Key facts
- V4Cure’s last known valuation is $5.9M (Mar 2026).
- It has raised $1.7M.
- Notable investors include Paris Biotech Sante.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for V4Cure
- ·The full record, as it builds
Funding rounds
No funding rounds for V4Cure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About V4Cure
Developer of peptide-derived therapeutics designed to treat cardio-renal diseases with unmet medical needs. The company offers venom-derived synthetic drug candidates with preclinical validation and a proprietary toxin-based discovery approach, enabling patients with cardio-renal and rare kidney disorders to have improved therapeutic options where existing treatments are limited.
- Sector
- Healthcare
- HQ
- Saint-Cloud, France
- Founded
- 2023
- Employees
- 1
- Website
- v4cure.com/
- Ownership
- Privately Held (backing)
V4Cure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in V4Cure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on V4Cure in its N-PORT filings yet. We sweep new filings monthly.